Mealey's (March 5, 2020, 1:40 PM EST) -- SAN FRANCISCO — Allegations of antitrust violations by a putative class in connection with patent settlement agreements between the makers of combination antiretroviral therapy (cART) drugs for the treatment of HIV will proceed, a California federal judge ruled March 3 (Staley, et al. v. Gilead Sciences Inc., et al., No. 19-2573, N.D. Calif., 2020 U.S. Dist. LEXIS 36747)....